# China NMPA Drug Inspection - Anhui Northwest Chinese Herbal Medicine Pieces Co., Ltd. - Cnidium monnieri

Source: https://www.globalkeysolutions.net/records/china_drug_inspection/anhui-northwest-chinese-herbal-medicine-pieces-co-ltd/1e984b78-c0ec-4dd2-9e5d-82e73a424ba3/
Source feed: China

> China NMPA drug inspection for Anhui Northwest Chinese Herbal Medicine Pieces Co., Ltd. published June 15, 2020. Drug: Cnidium monnieri. On June 15, 2020, the Henan Provincial Drug Administration published an announcement regarding its annual drug sampling 

---

## Details

- Record Type: CHINA_DRUG_INSPECTION
- Title: Announcement from Henan Provincial Drug Administration Regarding 12 Batches of Substandard Drugs (Issue 2, 2020)
- Company Name: Anhui Northwest Chinese Herbal Medicine Pieces Co., Ltd.
- Publication Date: 2020-06-15
- Drug Name: Cnidium monnieri
- Inspection Finding: [Inspection] - Total ash content and [content determination] did not meet the requirements; the labeled manufacturer denied that it produced the product.
- Action Taken: Control measures will be taken and the matter will be investigated and dealt with in accordance with the law. The enterprises or units involved will be required to take risk control measures such as suspending sales, use or recalling products. The reasons for non-compliance will be investigated and rectified in a thorough manner.
- Summary: On June 15, 2020, the Henan Provincial Drug Administration published an announcement regarding its annual drug sampling and inspection program, identifying 12 batches of substandard medications. The inspections targeted various drug manufacturers, distributors, and healthcare facilities throughout the province to ensure compliance with the Chinese Pharmacopoeia (2010 and 2015 editions). Key companies named in the report include Anhui Jiezhong Biochemical Co., Ltd., Anyang Huaan Pharmaceutical Co., Ltd., Hubei Jinlong Pharmaceutical Co., Ltd., and several others. Notably, manufacturers such as Tianma (Anhui) Sinopharm Technology and Hebei Jixintang Pharmaceutical Co., Ltd. denied producing the specific batches found in the market upon verification. The primary violations identified involve quality control failures, including excessive ash content, non-compliant microbial limits, weight variation in tablets, and failures in identification and content determination tests. To address these risks, the regulatory authority has ordered the immediate suspension of sales and use of the affected products. Companies are required to initiate product recalls, conduct formal investigations into the root causes of these quality failures, and implement thorough rectification measures to bring their operations back into compliance with national safety standards. Local regulatory departments are currently overseeing these enforcement actions and pursuing legal penalties where necessary.

Company: https://www.globalkeysolutions.net/companies/anhui-northwest-chinese-herbal-medicine-pieces-co-ltd/27a4c673-59af-4045-b2d6-87eefdfc15e5/